Meeting
2015 ASCO Annual Meeting
Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer (ROC).
Authors
Feriel Boumedien
Faculty of Medicine, Université de Montreal, Montreal, QC, Canada
Feriel Boumedien , Jean-Philippe Adam , Khalid Akkour , Nathalie LeTarte , Diane M. Provencher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 5553)
DOI
10.1200/jco.2015.33.15_suppl.5553
Abstract #
5553
Poster Bd #
111
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A GINECO phase I study evaluating lenalidomide (Le) combined with pegylated liposomal doxorubicin (PLD) and carboplatin (C) in late (>6 months) recurrent ovarian cancer (LROC) patients (pts).
First Author: Frédéric Selle
Poster
2023 ASCO Annual Meeting
Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer.
First Author: Robert L. Coleman
Poster
2023 ASCO Annual Meeting
A phase II trial of palbociclib combined to letrozole after progression on second-line chemotherapy for women with ER/PR-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer: LACOG 1018.
First Author: Fernanda Bronzon Damian
Poster
2022 ASCO Annual Meeting
Efficacy and toxicity of carboplatin and gemcitabine dosed on day 1/day 8 versus day 1 alone for platinum-sensitive recurrent epithelial ovarian cancer.
First Author: Erika Joelle Lampert